retatrutide gip glp-1 glucagon receptor agonist From Obesity to Metabolic Health: Why Is a Game-Changer Retatrutide Guide 2023: Weight Loss,

Phase 3 SYNCHRONIZE trials fully enrolled for obesity (results expected H1 2026)

Programs that address only weight will be evaluated against programs that address weight and its downstream burden

Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease

As estrogen levels decline, women may burn 250300 fewer calories per day, making weight gain easier and weight loss harder

High Density Lipoprotein (HDL)showed no significant increase with liraglutide treatment however, Exentide showed 24% HDL increase by Exentide twice daily injection